Genmab in cooperation with Dutch pharma company  

Biotech company Genmab in antibody development deal with Semaia Pharmaceuticals

Berlingske Tidende Online reports that the Danish biotech company Genmab has entered a cooperation agreement with the Dutch company Semaia Pharmaceuticals to jointly develop new therapeutic antibodies. Genmab will exploit its human antibody technology and its knowledge in the preclinical area to develop and manufacture up to four cancer target molecules which Semaia has discovered. Genmab and Semaia will cooperate on research, development and possible marketing of the new products. The companies will share development costs and income generated from sales or licensing on a 50/50 basis.


An offshoot of the US company Medarex, Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and plans to assemble a broad portfolio of new therapeutic products arising from research into the human genome. Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, The Netherlands and Princeton, New Jersey, US.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×